Srdan Verstovsek, MD:Once we are sure that the patient has polycythemia vera, the next step is to determine the patient’s risk for thrombosis. We know that patients with polycythemia vera are at increased risk for blood clotting, or thrombosis, in general. We can divide them into 2 groups. This is based on 2 factors. One factor is age over 60, and the other factor is history of blood clotting. If the patient has one or the other, he or she is at high risk for thrombosis.
In our particular case, the patient is newly diagnosed with polycythemia vera, never had a blood clot, and is younger than age 60. Therefore, the patient is at low risk for thrombosis. Patients who are at low risk for thrombosis with polycythemia vera are treated in a simple way. They are given baby aspirin (81 mg) to make the blood flow easier. The other treatment is phlebotomy. The aim of a phlebotomy is to decrease the hematocrit level, and the goal is to decease the hematocrit level to below 45%.
In the history of polycythemia vera, we always looked at the experimental information from dogs or other animal models. How would an increased risk of thrombosis correlate with the increased numbers of red blood cells that secrete around the blood, which is polycythemia vera? A few years ago, there was finally a prospective, randomized study done in Europe. The study randomized patients with polycythemia vera with an aim to maintain the hematocrit level below 45% or not to be so strict and allow the hematocrit level to be between 45% and 50%. This prospective, randomized study was stopped early, after about 3 years of follow-up, because it was quite clear that the group that had tight control of hematocritbelow 45%—had fewer thromboembolic events, or fewer clotting episodes. This led to fewer deaths from the complications of having those clots.
The main cause of death in polycythemia vera is linked to a thromboembolic event. So, if we follow what this prospective, randomized study showed (that tight control of hematocrit below 45% leads to fewer thromboembolic events, eventually decreasing the risk for death), that’s the ultimate goal. We should all be following tight control of hematocrit (45%) as the goal of therapy.
Transcript edited for clarity.
June 2016
October 2016
January 2017
Rossetti Reviews Myelofibrosis Risk Stratification and Outcome Data for Pacritinib
July 17th 2024During a Case-Based Roundtable® event, James M. Rossetti, DO, discussed the role of risk scoring and stratification tools and treatment for a patient with declining hemoglobin and platelet counts due to primary myelofibrosis.
Read More
Phase 3 VERIFY Trial Investigates Rusfertide’s Potential in Polycythemia Vera
July 16th 2024In an interview, Aniket Bankar, MD, discussed the background, design, and goals of the phase 3 VERIFY trial of the hepcidin mimetic rusfertide for the treatment of patients with polycythemia vera.
Read More
Ruxolitinib Treatment in Myelofibrosis Still Effective, Regardless of Anemia
June 21st 2024New or worsening anemia did not appear to reduce the clinical benefit of ruxolitinib in myelofibrosis patients, and the median overall survival was similar between patients with and without new or worsening anemia.
Read More
Challenging Disease Features of Myelofibrosis Lead to Use of JAK Inhibitors
June 17th 2024During a Case-Based Roundtable® event, Kristen Pettit, MD, moderated a discussion on which disease features of myelofibrosis are most challenging and when to use JAK inhibitors in the first article of a 2-part series.
Read More